Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2014 · 10-Q
Revenue$2.50K$2.50K−76.9% vs Q1 2013 Net Income-$7.62K-$7.62KN/M vs Q1 2013 EPS Diluted$0.00$0.00— vs Q1 2013 Operating Cash Flow-$127N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Net margin-304.8%−251.1 pt vs Q1 2013
ended Mar 31, 2014 · filed May 20, 2014 · 50 d after period end